Does the use of proton pump inhibitors in children affect ventricular repolarisation parameters?

Onur Tasci1, Ezgi Kiran Tasci2

  • 1Department of Pediatric Cardiology, Sivas Numune Hospital, Sivas, Turkey.

Insights

Proton pump inhibitors did not significantly alter ventricular repolarization parameters in children with dyspepsia. This study found no changes in corrected QT interval or other ECG measures, suggesting safety in this population.

Area of Science:

  • Cardiology
  • Pediatric Gastroenterology
  • Clinical Pharmacology

Background:

  • Proton pump inhibitors (PPIs) are common dyspepsia treatments.
  • Their impact on cardiac ion channels and ventricular repolarization is known.
  • Understanding PPI effects on pediatric cardiac electrophysiology is crucial.

Purpose of the Study:

  • To assess changes in electrocardiogram (ECG) ventricular repolarization parameters before and after PPI treatment in children with dyspepsia.
  • To evaluate the safety of PPIs regarding cardiac electrical activity in pediatric patients.

Main Methods:

  • A study involving 69 pediatric patients (mean age 13.16 years) with chronic dyspepsia symptoms.
  • ECG parameters including QT interval, corrected QT (QTc), and Tp-e were measured initially and after 1 month of PPI treatment.
  • Electrolyte levels were monitored before and after treatment.

Main Results:

  • No statistically significant differences were observed in QTc, Tp-e duration, or Tp-e/QT ratio post-PPI treatment.
  • Patient electrolyte levels remained within normal ranges throughout the study.
  • No ventricular arrhythmias were detected during the follow-up period.

Conclusions:

  • PPI treatment did not significantly prolong QTc duration or affect other ventricular repolarization parameters in children with dyspepsia.
  • While this study suggests PPIs are safe regarding ventricular repolarization in this group, larger studies and longer follow-up are warranted.
  • Caution is advised for drugs affecting QT interval, with potential need for serial ECG monitoring.

Related Concept Videos

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.8K
Cardiac Action Potential01:30

Cardiac Action Potential

Cardiac action potentials are essential for proper heart function, enabling the rhythmic contractions needed for adequate blood circulation. Nodal cells and Purkinje fibers, specialized for electrical conduction, generate these action potentials.
The cardiac action potential process involves a series of phases characterized by the movement of ions across the cardiac cell membranes, leading to the depolarization and repolarization of the cardiac myocytes.
Ionic Basis of Cardiac Action Potentials
2.9K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
1.1K
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
546
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
930
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.3K